Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Vaccine

• Publication date

  2009-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2009.09.018PMID 19761832
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of peripheral and local anti‐tumor immune response in esophageal cancer patients after NY‐ESO‐1 protein vaccination

  2008cited by this paper
• Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel

  2008cited by this paper
• Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

  2008cited by this paper
• Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting

  2007cited by this paper
• T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

  2007cited by this paper
• EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.

  2007cited by this paper
• The nature and consequences of intra- and inter-vaccine interference.

  2007cited by this paper
• Antibody response against NY‐ESO‐1 in CHP‐NY‐ESO‐1 vaccinated patients

  2007cited by this paper
• Heterogeneous expression of GAGE, NY‐ESO‐1, MAGE‐A and SSX proteins in esophageal cancer: Implications for immunotherapy

  2006cited by this paper
• HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan

  2006cited by this paper
• Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.

  2006cited by this paper
• HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival.

  2006cited by this paper
• Analyses of Recombinant Vaccinia and Fowlpox Vaccine Vectors Expressing Transgenes for Two Human Tumor Antigens and Three Human Costimulatory Molecules

  2005cited by this paper
• Expression Profile of Cancer-Testis Genes in 121 Human Colorectal Cancer Tissue and Adjacent Normal Tissue

  2005cited by this paper
• Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma

  2005cited by this paper
• Expression of Toll-Like Receptor 4 on Dendritic Cells Is Significant for Anticancer Effect of Dendritic Cell-Based Immunotherapy in Combination with an Active Component of OK-432, a Streptococcal Preparation

  2004cited by this paper
• NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer

  2004cited by this paper
• NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer

  2004cited by this paper
• Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination

  2003cited by this paper
• c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma.

  2003cited by this paper
• CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

  2003cited by this paper
• Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.

  2002cited by this paper
• Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues

  2001cited by this paper
• Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• T Cells Compete for Access to Antigen-Bearing Antigen-Presenting Cells

  2000cited by this paper
• A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.

  1998cited by this paper
• Clinically Relevant Vaccine-Vaccine Interactions

  1998cited by this paper
• A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

  1998cited by this paper
• Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis.

  1997cited by this paper
• Macromolecular Complexation between Bovine Serum Albumin and the Self-Assembled Hydrogel Nanoparticle of Hydrophobized Polysaccharides

  1996cited by this paper

• Antitumor immune response elicited by M2 TAM-specific DDS via C-type lectin CD209b using cholesteryl pullulan nanogel as a protein drug carrier.

  2025cites this paper
• The paths toward immunotherapy of esophageal cancer: An overview of clinical trials.

  2025cites this paper
• A phase 1 trial of NY‐ESO‐1‐specific TCR‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma

  2023cites this paper
• Nanogels as target drug delivery systems in cancer therapy: A review of the last decade

  2022cites this paper
• Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients

  2021cites this paper
• Advanced Hydrogels for the Controlled Delivery of Insulin

  2021cites this paper
• First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors

  2020cites this paper
• Immunotherapy of Gastric and Esophageal Cancers

  2020cites this paper
• Recent Advances in Degradable Hybrids of Biomolecules and NGs for Targeted Delivery

  2019influential citation
• Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance

  2019cites this paper
• A Systematic Review and Meta-analysis: Vinegar Consumption on Glycemic Control in Adults with Type 2 Diabetes Mellitus.

  2019cites this paper
• Immunomodulatory Nanosystems

  2019cites this paper
• NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma

  2018cites this paper
• Specific Features of Transcription Activity of Cancer-Testis Antigens in Patients with Metastatic and Non-Metastatic Breast Cancer

  2018cites this paper
• Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination

  2018cites this paper
• Research progress of self-assembled nanogel and hybrid hydrogel systems based on pullulan derivatives

  2018cites this paper
• TRANSCRIPTIONAL PROFILE OF CANCER-TESTICULAR ANTIGENS IN PATIENTS WITH BREAST CANCER

  2018cites this paper
• Translational nanoparticle engineering for cancer vaccines

  2017cites this paper
• Pullulan: A novel molecule for biomedical applications.

  2017cites this paper
• Possible functions of CD169‐positive sinus macrophages in lymph nodes in anti‐tumor immune responses

  2017cites this paper
• Basic concepts and recent advances in nanogels as carriers for medical applications

  2017cites this paper
• Pivotal Role of Lymph Node Sinus Macrophages and Anti-Tumor Immune Responses in Patients with Malignant Tumors

  2017cites this paper
• Nanocellulose and Nanogels as Modern Drug Delivery Systems

  2017cites this paper
• Immunotherapy for Gastroesophageal Cancer

  2016cites this paper
• Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel

  2016cites this paper
• New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.

  2015cites this paper
• Current advances in self-assembled nanogel delivery systems for immunotherapy.

  2015influential citation
• Tumor Immunotherapy of Esophageal and Gastric Cancers

  2015cites this paper
• Polysaccharide-based self-assembling nanohydrogels: An overview on 25-years research on pullulan

  2015cites this paper
• Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy.

  2014cites this paper
• Investigational therapies targeting the ErbB family in oesophagogastric cancer

  2014cites this paper
• Vaccination With NY-ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY-ESO-1 Antigen

  2014cites this paper
• Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients.

  2014cites this paper
• Vaccination with antigen-transfected, NKT cell ligand-loaded, human cells elicits robust in situ immune responses by dendritic cells.

  2013cites this paper
• Limited expression of cancer-testis antigens in renal cell carcinoma patients.

  2013cites this paper
• Overcoming regulatory T‐cell suppression by a lyophilized preparation of Streptococcus pyogenes

  2013cites this paper
• Polymeric nanogels as vaccine delivery systems.

  2013cites this paper
• Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.

  2013cites this paper
• Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients

  2013cites this paper
• Functional nanogels for biomedical applications.

  2012cites this paper
• Trypanosoma cruzi Adjuvants Potentiate T Cell-Mediated Immunity Induced by a NY-ESO-1 Based Antitumor Vaccine

  2012cites this paper
• Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion

  2012cites this paper
• Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder.

  2012cites this paper
• Trypanosoma cruzi as an effective cancer antigen delivery vector

  2011cites this paper
• Nanoparticles and modulation of immune responses

  2011cites this paper
• Therapeutic cancer vaccines: are we there yet?

  2011cites this paper
• Therapeutic vaccines for gastrointestinal cancers.

  2011cites this paper
• Vaccine-induced antibody responses in patients with carcinoma

  2010cites this paper